Literature DB >> 1195468

Chemotherapy of bladder carcinoma with cyclophosphamide and adriamycin.

C Merrin, R Cartagena, Z Wajsman, G Baumgartner, G P Murphy.   

Abstract

We assigned 49 patients with transitional cell carcinoma of the bladder to 1 of 3 groups: 21 patients (group 1) received cyclophosphamide alone, 10 patients (group 2) received adriamycin alone and 18 patients (group 3) received cyclophosphamide and adriamycin. The objective responses were 52.3 per cent in group 1, 10 per cent in group 2 and 50 per cent in group 3. These results suggest a significant activity of the drugs (especially in groups 1 and 3) tested in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1195468     DOI: 10.1016/s0022-5347(17)67165-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Three-drug combination chemotherapy for advanced urothelial tract carcinoma.

Authors:  S Ohshima; Y Ono; T Fujita; Y Aso
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Chemotherapy in bladder cancer.

Authors: 
Journal:  Br Med J       Date:  1977-12-17

Review 3.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).

Authors:  P H Smith; J A Child; J H Mulder; A T Van Oosterom; J A Martinez-Pineiro; B Richards; G Stoter; O Dalesio; M De Pauw; R Sylvester
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Combination chemotherapy for advanced urothelial-tract carcinoma.

Authors:  M Sahashi; Y Ono; O Matsuura; S Ohshima; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Chemotherapy in the management of invasive bladder cancer. A review.

Authors:  H Bush; N Thatcher; R Barnard
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.